作者
S Yusuf, K Teo, Craig Anderson, J Pogue, L Dyal, I Copland, H Schumacher, G Dagenais, P Sleight, B Ramos, L Richardson, J Murphy, M Haehl, L Hilbrich, R Svaerd, K Martin, D Murwin, T Meinicke, A Schlosser, G Schmidt, R Creek, M Distel, B Aubert, R Schmieder, T Unger, R Asmar, G Mancia, R Diaz, E Paolasso, L Piegas, A Avezum, J Probstfield, M Weber, J Young, R Fagard, P Jansky, J Mallion, J Mann, M Böhm, B Eber, NB Karatzas, M Keltai, B Trimarco, P Verdecchia, A Maggioni, FW Verheugt, NJ Holwerda, L Ceremuzynski, A Budaj, R Ferreira, I Chazova, L Rydén, TL Svendsen, K Metsärinne, K Dickstein, G Fodor, P Commerford, J Redon, TR Luescher, A Oto, A Binbrek, A Parkhomenko, G Jennings, LS Liu, CM Yu, AL Dans, R Shah, JH Kim, JH Chen, S Chaithiraphan, J Cairns, L Wilhelmsen, J Chalmers, J Wittes, M Gent, CH Hennekens, N Anderson, K Yusoff, P Auger, V Bernstein, E Lonn, A Panju, I Anand, JT Bigger, P Linz, J Healey, C Held, C McGorrian, M Rokoss, J Villar, A Dans, A McDonald, D Schweitzer, J Cunningham, E Wagan, T Boland, L Westfall, N Gulliver, R Oliveira, C McLean-Price, S Kotlan, F Tosto, R Afzal, F Zhao, Ahuad Guerrero RA, M Amuchastegui, HP Baglivo, M Bendersky, J Bono, B Bustos, A Caccavo, LR Cartasegna, CR Castellanos, M Cipullo, CA Cuneo, JJ Fuselli, GJ Guaymas, E Hasbani, MA Hominal, JD Humphreys, CR Killinger, E Kuschnir, CR Majul, EM Marzetti, R Nordaby, AD Orlandini, OB Paez, JA Piasentin, JC Pomposiello, JH Resk, GM Rodríguez, Said Nisi, JM Sala, RA Sanchez, PO Schygiel, C Serra, ML Vico, GL Jennings, JV Amerena, LF Arnolda, PE Aylward, CF Bladin, BR Chambers, DS Crimmins, DB Cross, L Davies, SM Davis, DS Eccleston, JH Frayne, GK Herkes
发表日期
2008
期刊
Lancet
卷号
372
期号
9644
页码范围
1174-1183
简介
BACKGROUND
Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage.
METHODS
After a 3-week run-in period, 5926 patients, many of whom were receiving concomitant proven therapies, were randomised to receive telmisartan 80 mg/day (n=2954) or placebo (n=2972) by use of a central automated randomisation system. Randomisation was stratified by hospital. The primary outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00153101.
FINDINGS
The median duration of …
引用总数
学术搜索中的文章
Telmisartan Randomised AssessmeNt Study in ACE … - The Lancet, 2008